In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors.
Jay R AnandDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0003-2071-9891 Gaith N DrobyCurriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599, USA.
Sayali JosephDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-2583-7080 Urvi PatelDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0009-0005-0075-6507 Xingyuan ZhangDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0009-0009-9072-948X Jeffrey A KlompLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-5243-6987 Channing J DerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7751-2747 Jeremy E PurvisDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Samuel C WolffDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-2530-5858 Jessica BowserDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0003-0655-7769 Cyrus VaziriDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-3081-8685 Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MA Novel Carcinogen-Induced Cell Cycle CheckpointR01ES009558 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS · 2002 to 2016
$4.8MDefining Mechanisms of Pathological Trans-Lesion Synthesis During CarcinogenesisR01CA215347 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS, WILLIAMS, SCOTT E · 2018 to 2022
$2.6MEstablishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic targetR01CA229530 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.0MAndor Dragonfly 202 Spinning Disk Confocal Microscope for the University of North Carolina at Chapel HillS10OD030223 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARIEL, PABLO · 2021 to 2021
$474kNCI NIH HHS P30 CA016086NCI NIH HHS R01 CA215347NCI NIH HHS R01 CA229530NIEHS NIH HHS R01 ES009558NIH HHS S10 OD030223
6 · The paper itselfAbstract
Oncogene activation in normal untransformed cells induces DNA replication stress and creates a dependency on DNA Damage Response (DDR) mechanisms for cell survival. Different oncogenic stimuli signal via distinct mechanisms in every cancer setting. The DDR is also pathologically re-programmed and deployed in diverse ways in different cancers. Because mutant KRAS is the driver oncogene in 90% of Pancreatic Ductal Adenocarcinomas (PDAC), here we have investigated DDR mechanisms by which KRAS-induced DNA replication stress is tolerated in normal human pancreatic epithelial cells (HPNE). Using a candidate screening approach, we identify TRIP13 as a KRAS
Identifiers
PMID39975297
PMCPMC11838190
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390